Insider Trading Alert - VR, NDAQ And CNC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 16, 2014, 80 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.26 to $11,203,447.50.

Highlighted Stocks Traded by Insiders:

Validus Holdings (VR) - FREE Research Report

Driscoll Kean, who is CEO, Validus Reinsurance, Ltd. at Validus Holdings, sold 3,276 shares at $38.76 on Sept. 16, 2014. Following this transaction, the CEO, Validus Reinsurance, Ltd. owned 145,705 shares meaning that the stake was reduced by 2.2% with the 3,276-share transaction.

The shares most recently traded at $39.22, up $0.46, or 1.17% since the insider transaction. Historical insider transactions for Validus Holdings go as follows:

  • 4-Week # shares sold: 3,276
  • 12-Week # shares bought: 48
  • 12-Week # shares sold: 13,052
  • 24-Week # shares bought: 48
  • 24-Week # shares sold: 16,328

The average volume for Validus Holdings has been 469,200 shares per day over the past 30 days. Validus Holdings has a market cap of $3.6 billion and is part of the financial sector and insurance industry. Shares are down 2.95% year-to-date as of the close of trading on Tuesday.

Validus Holdings, Ltd. provides reinsurance coverage, insurance coverage, and insurance linked securities management services worldwide. It operates through three segments: Validus Re, AlphaCat, and Talbot. The stock currently has a dividend yield of 3.07%. The company has a P/E ratio of 6.5. Currently, there are 5 analysts who rate Validus Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VR - FREE

TheStreet Quant Ratings rates Validus Holdings as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Validus Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NASDAQ OMX Group (NDAQ) - FREE Research Report

Aust Bruce, who is Executive Vice President at NASDAQ OMX Group, sold 26,389 shares at $43.75 on Sept. 16, 2014. Following this transaction, the Executive Vice President owned 72,350 shares meaning that the stake was reduced by 26.73% with the 26,389-share transaction.

The shares most recently traded at $43.90, up $0.15, or 0.34% since the insider transaction. Historical insider transactions for NASDAQ OMX Group go as follows:

  • 4-Week # shares sold: 100,222
  • 12-Week # shares sold: 165,484
  • 24-Week # shares sold: 189,197

The average volume for NASDAQ OMX Group has been 1.1 million shares per day over the past 30 days. NASDAQ OMX Group has a market cap of $7.4 billion and is part of the financial sector and financial services industry. Shares are up 10.48% year-to-date as of the close of trading on Tuesday.

The NASDAQ OMX Group, Inc. delivers trading, clearing, exchange technology, regulatory, securities listing, and public company services worldwide. It operates in four segments: Market Services, Listing Services, Information Services, and Technology Solutions. The stock currently has a dividend yield of 1.37%. The company has a P/E ratio of 16.4. Currently, there are 6 analysts who rate NASDAQ OMX Group a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NDAQ - FREE

TheStreet Quant Ratings rates NASDAQ OMX Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full NASDAQ OMX Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Centene (CNC) - FREE Research Report

Williamson Keith H, who is EVP, Secr. & General Counsel at Centene, sold 4,000 shares at $77.48 on Sept. 16, 2014. Following this transaction, the EVP, Secr. & General Counsel owned 57,571 shares meaning that the stake was reduced by 6.5% with the 4,000-share transaction.

The shares most recently traded at $79.39, up $1.91, or 2.41% since the insider transaction. Historical insider transactions for Centene go as follows:

  • 4-Week # shares bought: 17,600
  • 4-Week # shares sold: 12,000
  • 12-Week # shares bought: 17,600
  • 12-Week # shares sold: 12,000
  • 24-Week # shares bought: 17,600
  • 24-Week # shares sold: 19,500

The average volume for Centene has been 964,500 shares per day over the past 30 days. Centene has a market cap of $4.5 billion and is part of the health care sector and health services industry. Shares are up 33.93% year-to-date as of the close of trading on Tuesday.

Centene Corporation provides multi-line healthcare programs and services in the United States. It operates in two segments, Managed Care and Specialty Services. The company has a P/E ratio of 25.0. Currently, there are 8 analysts who rate Centene a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CNC - FREE

TheStreet Quant Ratings rates Centene as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, growth in earnings per share, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Centene Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing